We tested the Raboral V-RG® recombinant oral rabies vaccine for its response in Arctic foxes (Vulpes lagopus), the reservoir of rabies virus in the circumpolar North. The vaccine, which is currently the only licensed oral rabies vaccine in the United States, induced a strong antibody response and protected foxes against a challenge of 500,000 mouse intracerebral lethal dose 50% of an Arctic rabies virus variant. However, one unvaccinated control fox survived challenge with rabies virus, either indicating a high resistance of Arctic foxes to rabies infection or a previous exposure that induced immunity. This preliminary study suggested that Raboral V-RG vaccine may be efficacious in Arctic foxes.
Preliminary Evaluation of Raboral V-RG® Oral Rabies Vaccine in Arctic Foxes (Vulpes lagopus)
- Views Icon Views
- PDF LinkPDF
- Share Icon Share
- Search Site
Erich Follmann, Don Ritter, Rhonda Swor, Mike Dunbar, Karsten Hueffer; Preliminary Evaluation of Raboral V-RG® Oral Rabies Vaccine in Arctic Foxes (Vulpes lagopus). J Wildl Dis 1 October 2011; 47 (4): 1032–1035. doi: https://doi.org/10.7589/0090-3558-47.4.1032
Download citation file: